Sanctuary Advisors LLC Takes $75,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

Sanctuary Advisors LLC bought a new position in scPharmaceuticals Inc. (NASDAQ:SCPH) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 16,555 shares of the company’s stock, valued at approximately $75,000.

A number of other large investors also recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its holdings in shares of scPharmaceuticals by 35.5% in the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after buying an additional 1,250,000 shares during the period. Bank of Montreal Can purchased a new position in scPharmaceuticals in the 2nd quarter worth approximately $1,544,000. King Luther Capital Management Corp lifted its position in scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock valued at $9,592,000 after purchasing an additional 752,005 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of scPharmaceuticals by 76.9% during the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of scPharmaceuticals in the third quarter worth approximately $124,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SCPH shares. Craig Hallum lowered their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, November 14th.

scPharmaceuticals Price Performance

SCPH opened at $3.50 on Tuesday. The stock’s 50 day moving average price is $3.70 and its 200-day moving average price is $4.32. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.60. The stock has a market capitalization of $175.14 million, a PE ratio of -1.84 and a beta of 0.14. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.